Bristol Myers Squibb Co $51.12

up +0.11


30/7/2014 04:03 PM  |  NYSE : BMY  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get BMY Trend Analysis - it has outperformed the S&P 500 by 1%

Partner Headlines

  1. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  2. Bristol-Myers surprises Street

    IBD
  3. Thursday Morning Earnings Reports

    Benzinga
  4. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  5. Earnings Scheduled For July 24, 2014

    Benzinga
  6. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  7. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions ...

    Benzinga
  8. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  9. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  10. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  11. Bristol seeks cancer drug nod

    IBD
  12. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  13. Japan approves BMY regimen

    IBD
  14. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  15. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  16. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  17. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  18. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  19. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target By 41%

    Benzinga
  20. Benzinga's Top Downgrades

    Benzinga
  21. Ex-Dividends For July 1, 2014

    Benzinga
  22. Pfizer and others get EU nods

    IBD
  23. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  24. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  25. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  26. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment ...

    Benzinga
  27. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  28. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  29. BRISTOL-MYERS SQUIBB

    IBD
  30. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped ...

    Benzinga
  31. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  32. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  33. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  34. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  35. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  36. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  37. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  38. Bristol, Merck Q1 sales soft

    IBD
  39. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  40. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, TWTR)

    Benzinga
  41. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
  42. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  43. Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone Payments ...

    Benzinga
  44. Earnings Scheduled For April 29, 2014

    Benzinga
  45. Stocks To Watch For April 29, 2014

    Benzinga
  46. Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump

    IBD
  47. Earnings Expectations For The Week Of April 28: Big Oil, Big Pharma And ...

    Benzinga
  48. Benzinga Weekly Preview: Earnings Season Continues As Biotech & Pharmaceutical ...

    Benzinga
  49. Week Ahead: April Jobs Report, FOMC Meeting and Earnings

    FoxBusiness
  50. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
Trading Center